Shandong Aonai Biopharmaceutical Co., Ltd., a leading pet probiotics manufacturer and pet health supplier based in Linyi City, Shandong Province, China, has announced that its Dutch invention patent application, titled "DR.KALAN COMPOUND PROBIOTIC, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF" (a Dr.kalan compound probiotic and its preparation method and application), has been registered and published by the Netherlands Patent Office (Octrooicentrum Nederland) under publication number NL 4000956 A. This milestone strengthens the company's core technology position in the rapidly growing pet gut health category.
Application number: 4000956
Filing date: February 4, 2026
Registration date: April 17, 2026
Publication date: April 23, 2026
Applicant: Shandong Aonai Biopharmaceutical Co., Ltd. (No. 2-1, Factory Building, Wenshui Industrial Park, North of National Highway 327, Wenshui Town, Pingyi County, Linyi City, Shandong Province, China)
Inventor: Jianxin Zhang
IPC classification: A23K 10/18 (feed microorganisms), A23K 50/40 (dog and cat feed), A61K 35/742 (microbial preparations)
With the rapid growth of the "pet economy," gut health has become one of the most discussed health topics among pet owners. Dog probiotics and cat probiotics are among the highest-demand pet supplement categories globally. Yet the market has long faced three technical bottlenecks:
1. Low colonization rate: many products use human-derived or generic strains that colonize poorly in canine and feline intestines, delivering only short-lived benefits;
2. Poor stability: probiotic activity is sensitive to temperature and humidity, so viable counts drop sharply during shelf life, making product efficacy unreliable;
3. Insufficient efficacy: single strains or simple blends cannot handle complex scenarios such as diet transitions, travel stress, and environmental changes.
After years of research, Shandong Aonai's R&D team developed the Dr.kalan compound probiotic technology to solve these problems, filing the invention patent application in the Netherlands as the first step of its international IP strategy.
The invention discloses a Dr.kalan compound probiotic consisting, by mass percentage, of:
78%‒82% core strain group ― the primary functional component;
18%‒22% functional auxiliary components ― synergistically supporting strain activity;
1%‒4% carrier materials ― protecting viability and stability.
To ensure the uniqueness and verifiability of the strains, the core strains have been deposited at the China General Microbiological Culture Collection Center (CGMCC, Institute of Microbiology, Chinese Academy of Sciences) under deposit numbers 10701, 13044, 17225, and 19824, providing solid legal and scientific protection for product exclusivity and quality traceability.
Compared with existing similar products, the Dr.kalan compound probiotic delivers four significant advantages:
1. Strong strain specificity and superior colonization. The product uses a strain combination optimized for canine and feline intestinal environments, achieving an intestinal colonization rate 35% higher than human-derived strains ― addressing the industry-wide problem of "supplements that seem to do nothing."
2. Significantly improved stability. Supported by the company's proprietary coating technology, the product maintains a 24-month shelf life at room temperature with a viable bacteria retention rate of no less than 80%, effectively solving the activity-loss problem during warehousing, shipping, and retail shelf life.
3. Obvious synergistic efficacy. The scientific combination of the core strain group and functional auxiliary components produces a clear synergistic effect: under stress conditions such as diet changes or travel, the improvement rate of intestinal problems increases by more than 50%, helping pets get through special periods smoothly.
4. High industrialization feasibility. Standardized process parameters and low viable bacteria loss make the product fully suitable for large-scale industrial production, meeting the sustained global demand for high-quality pet probiotics.
The Dr.kalan compound probiotic can be applied to daily gut care for dogs and cats, stress-period intestinal regulation, and immune support. Beyond finished retail products, the technology is available for OEM/ODM, private label, and bulk supply programs, enabling pet food brands, distributors, and retailers to launch their own probiotic product lines quickly with a proven, patented formulation. For buyers searching for a private label dog probiotics partner or a pet probiotic powder supplier, this patent publication serves as strong evidence of the company's R&D depth and production capability.
Shandong Aonai Biopharmaceutical Co., Ltd. is a science-driven pet health enterprise located in the Wenshui Industrial Park, Pingyi County, Linyi City, Shandong Province, China. The company integrates R&D, production, and sales, with a product portfolio spanning dog joint supplements, dog multivitamins, dental care products, and digestive & probiotic supplements under its Dr.kalan brand. As an experienced pet supplement manufacturer and supplier, the company offers flexible OEM/ODM, private label, and custom formula services to brands and distributors worldwide. Its quality assurance system is backed by an FSPCA PCQI-certified R&D team, and the company holds multiple international invention patent applications covering its Dr.kalan compound probiotics and gastric acid-resistant collagen peptides. Committed to "quality first, safety first, technology driven," Shandong Aonai is dedicated to delivering safe, scientific, and premium pet health products to pets and pet parents around the world.
Looking ahead, Shandong Aonai Biopharmaceutical will continue to strengthen its Dr.kalan brand, expand its international IP portfolio, and work with global partners to share the growth dividends of the pet economy.
EN
